Spero Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2015 to 2021

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Spero Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2015 to 2021.
  • Spero Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$17.9M, a 50.4% decline year-over-year.
  • Spero Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$89.8M, a 14.7% decline from 2020.
  • Spero Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2020 was -$78.3M, a 28.6% decline from 2019.
  • Spero Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2019 was -$60.9M, a 46% decline from 2018.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2021 -$89.8M -$11.5M -14.7% Jan 1, 2021 Dec 31, 2021 10-K 2022-03-31
2020 -$78.3M -$17.4M -28.6% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-31
2019 -$60.9M -$19.2M -46% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-11
2018 -$41.7M -$2.96M -7.63% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-16
2017 -$38.7M -$13.3M -52% Jan 1, 2017 Dec 31, 2017 10-K 2019-03-14
2016 -$25.5M -$15.3M -150% Jan 1, 2016 Dec 31, 2016 10-K 2019-03-14
2015 -$10.2M Jan 1, 2015 Dec 31, 2015 10-Q 2018-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.